United States· US:0173-0873_4049ca45-7739-4d4a-bcce-50c5b3c7415f
Incruse Ellipta
A medicinal product containing umeclidinium bromide, registered in United States by GlaxoSmithKline LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- UMECLIDINIUM BROMIDE
- Manufacturer
- GlaxoSmithKline LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1101730873061 TRAY in 1 CARTON (0173-0873-06) / 1 INHALER in 1 TRAY / 7 AEROSOL, POWDER in 1 INHALER
- ndc1101730873101 TRAY in 1 CARTON (0173-0873-10) / 1 INHALER in 1 TRAY / 30 AEROSOL, POWDER in 1 INHALER
- ndc110173-0873-10
- ndc110173-0873-06
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Umeclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIncruse Ellipta 55micrograms/dose dry powder inhalerDE Pharmaceuticals
- CzechiaINCRUSE ELLIPTAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumElebrato Ellipta 92 µg/dose - 22 µg/doseGlaxoSmithKline Trading Services
- SpainINCRUSE ELLIPTA 55 mcg POLVO PARA INHALACION UNIDOSISGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaParanova Oy
- IrelandIncruse Ellipta 55 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
- SwitzerlandIncruse Ellipta
- NetherlandsIncruse Ellipta 55 microgram inhalatiepoeder, voorverdeeldGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Incruse Ellipta, Rolufta Ellipta
- Liechtenstein · Incruse Ellipta, Rolufta Ellipta
- Norway · Incruse Ellipta, Rolufta Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f7b2e269-5543-4b60-9770-7e5e6d345267 GET /v1/drugs/f7b2e269-5543-4b60-9770-7e5e6d345267?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "62.5",
"substance": "UMECLIDINIUM BROMIDE",
"productndc": "0173-0873",
"dosage_form": "AEROSOL, POWDER",
"dea_schedule": null,
"strength_unit": "ug/1",
"application_number": "NDA205382",
"marketing_category": "NDA"
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.